BEAM THERAPEUTICS INC (BEAM)
Health Care · gene editing / precision genetic medicines · NASDAQ
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders.
What BEAM THERAPEUTICS INC does
Beam Therapeutics is a clinical-stage biotechnology company developing base editing medicines for the treatment of serious genetic diseases. The company focuses on precision genetic medicines designed to cure patients through base editing technology, with a portfolio of clinical and preclinical programs targeting conditions including sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease type 1a. Beam is advancing both viral and non-viral delivery modalities, including novel lipid nanoparticles, to expand the applicability of gene editing across multiple tissue types.
Themes: ["genetic medicines / gene editing","base editing","rare genetic diseases","sickle cell disease","precision medicine"]
Fundamentals
- Price$35.82 as of 2026-07-09 close
- Market cap$3.7B as of 2026-07-10
- 1-year return+66.9% as of 2026-07-09 close
- Net margin-39.7% as of 2026-07-10
- ROE-5.9% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Revenue growth (YoY)+158.0% as of 2026-07-10
- Revenue CAGR (3y)+31.9% SEC XBRL
- Beta2.20 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Company must successfully advance multiple Phase 1/2 and preclinical programs through regulatory approval, with no guarantee of efficacy or safety demonstrations that satisfy regulators","Delivery modality challenges: Success depends on developing and validating novel lipid nanoparticles and other delivery systems to expand base editing beyond liver to other tissue types","Manufacturing and scaling: Company must maintain and scale cGMP manufacturing capacity for commercial production while managing significant R&D cash burn"]
Competitors & peers
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDTX)
- Intellia Therapeutics (NTLA)
- Sangamo Therapeutics (SGMO)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.